

Supplementary Materials: Bile Acid Dysregulation Is Intrinsically Related to Cachexia in Tumor-Bearing Mice

Morgane M. Thibaut, Justine Gillard, Adeline Dolly, Martin Roumain, Isabelle A. Leclercq, Nathalie M. Delzenne, Giulio G. Muccioli and Laure B. Bindels




Figure S1. TGR5 activation capacity incubated with individual bile acids and mouse portal plasma with or without TGR5 plasmid. TGR5 activation capacity using cell reporter assay incubated with FBS-free medium (Medium) or FBS-free medium containing 10 μ M of tauro-lithocholic acid (TLCA), tauro-cholic acid (TCA), tauro-chenodeoxycholic acid (TCDCA), tauro- α -muricholic acid (T α -MCA), tauro- β -muricholic acid (T β -MCA), tauro-deoxycholic acid (TDCA) and tauro-ursodeoxycholic acid (TUDCA) or pool of 10% portal plasma sham-injected mice (CT), mice injected with cachexia-inducing C26 colon carcinoma cells (C26) and mice injected with non-cachexia-inducing C26 colon carcinoma cells (NC) in cells transfected with pGL4.29 and pGL4.73, with or without pCMV-SPORT6 human TGR5 for 3 hours. Each condition was performed in three technical replicates, excepted for NC Pool (in two replicates).




Figure S2. Hepatic TGR5 agonist levels correlate with TGR5 activation capacity in mouse portal plasma. Correlation between hepatic TGR5 agonist levels and TGR5 activation capacity in portal plasma of sham-injected mice (CT; black spots; $n = 8$), mice injected with cachexia-inducing C26 colon carcinoma cells (C26 mice; red squares; $n = 10$) and mice injected with non-cachexia-inducing C26 colon carcinoma cells (NC mice; blue triangles; $n = 14$). $** p < 0.01$.




Figure S3. Tumor, liver, brown adipose tissue weights and hepatic bile acid profile in cachectic mice treated with ursodeoxycholic acid. **(a)** Tumor, liver and brown adipose tissue weights of sham-injected mice (CT), sham-injected mice treated with UDCA (CT-UDCA), mice injected with cachexia-inducing C26 colon carcinoma cells (C26) and mice injected with cachexia-inducing C26 colon carcinoma cells and treated with UDCA (C26-UDCA). **(b)** Hepatic bile acids in CT, CT-UDCA, C26 and C26-UDCA mice. $n = 7$ – 8 mice per group; data are presented as mean \pm SEM. ** $p < 0.01$, *** $p < 0.001$ CT vs CT-UDCA and # $p < 0.05$ ## $p < 0.01$, ### $p < 0.001$ C26 vs C26-UDCA. ND, Not detected; NQ, Not quantified.

Table S1. The primer sequences for the targeted mouse genes.

Target name	Alias/full name	Forward	Reverse
<i>Rpl6</i>	Ribosomal Protein L6	CTTGTGACTGGCCTCTGT	GCGTCAGTCAGGTGTTGG
<i>Oaz1</i>	ornithine decarboxylase antizyme 1	TCATCTGCTTCCCAAGAAC	TGGACCTAGTCCTCCTCAC
<i>Ntcp</i>	Na(+)/taurocholate transport protein	GGACAAGGTGCCCTACAAAG	ACAGCCACAGAGAGGGAGAA
<i>Oatp1b2</i>	organic anion transporter family member 1B2	ATCCCGTGACTAATCCAACA	ACCAAAGTCTGCTCTATAAACT
<i>Bsep</i>	bile salt export pump	AGATACAACCGAAGGGGACA	TCAACTTCTTCCACAAGCACA
<i>Mrp2</i>	Multidrug resistance-associated protein 2	GGATGGTGACTGTGGGCTGAT	GGCTGTTCTCCCTTCTCATGG
<i>Ostβ</i>	Organic solute transporter subunit beta	GTATTTTCGTGCAGAAGATGCG	TTTCTGTTGCCAGGATGCTC
<i>Cyp7a1</i>	cytochrome P450 family 7 subfamily A member 1	GGGATTGCTGTGGTAGTGAGC	GGTATGGAATCAACCCGTTGTC
<i>Cyp8b1</i>	cytochrome P450 family 8 subfamily B member 1	GATCCGTCGCGGAGATAAGG	CGGGTTGAGGAACCGATCAT
<i>Cyp27a1</i>	cytochrome P450 family 27 subfamily A member 1	TCTGGCTACCTGCACTTCCT	GTGTGTTGGATGTCGTGTCC
<i>Dio2</i>	iodothyronine deiodinase 2	AATTATGCCTCGGAGAAGACCG	GGCAGTTGCCTAGTGAAAGGT
<i>Ucp1</i>	uncoupling protein 1	GCTACACGGGGACCTACAATG	CGTCATCTGCCAGTATTTTGT
<i>Acox1</i>	acyl-CoA oxidase 1	CTATGGGATCAGCCAGAAAGG	AGTCAAAGGCATCCACCAAAG
<i>Cidea</i>	cell death inducing DFFA like effector a	TGGAAGAGGGACAGAAATGG	TCTCGTACATCGTGGCTTTG
<i>Gk</i>	glycerol kinase	TTTGTTCCTCAAACCCGAGAG	AGCGCCTAGTGCAGTTGTTT
<i>Il1β</i>	interleukin-1β	TCGCTCAGGGTACAAGAAA	CATCAGAGGCAAGGAGGAAAAC
<i>Ccl2</i>	C-C motif chemokine ligand 2	GCAGTTAAGCCCCACTCA	TCCAGCCTACTCATTTGGGATCA
<i>Cxcl1</i>	C-X-C motif chemokine ligand 1	AAACCGAAGTCATAGCCACAC	AAGCCAGCGTTTACCAGA
<i>Cxcl2</i>	C-X-C motif chemokine ligand 2	CGCCCAGACAGAAGTCATAG	CTCCTCCTTCCAGGTCAGTT
<i>Icam1</i>	intercellular adhesion molecule 1	GAGAGTGGACCCAACTGGAA	CACACTCTCCGGAACGAA
<i>Mmp8</i>	matrix metalloproteinase 8	CCTTCTACCCAACGGTCTT	GCCCAGTACTGTCTGCCTTT
<i>Vcam1</i>	vascular cell adhesion molecule 1	GAACCCAAACAGAGGCAGAG	CCATCACTTGAGCAGGTCAG
<i>Nlrp3</i>	NLR family pyrin domain containing 3	GCCCAAGGAGGAAGAAGAAG	AGAAGAGACCACGGCAGAAG
<i>Trim63</i>	Tripartite Motif Containing 63	ACGAGAAGAAGAGCGAGC	CTTGGCACTTGAGAGGAA
<i>Fbxo32</i>	F-Box Protein 32	ATGCACACTGGTGCAGAGAG	TGTAAGCACACAGGCAGGTC
<i>Musa1</i>	muscle ubiquitin ligase of the SCF complex in atrophy 1	TTCTTGACGGCTTCAGTTT	TGAATCGCCATACCTTCTCTTT
<i>Map1lc3a</i>	Microtubule Associated Protein 1 Light Chain 3 Alpha	CACTGCTCTGTCTTGTGTAGGTTG	TCGTGTGCCCTTTATTAGTGCATC
<i>Ctsl</i>	Cathepsin L	GTGGACTGTTCTACGCTCAAG	TCCGTCTTCGCTTCATAGG
<i>MyoG</i>	myogenin	CAGTGAATGCAACTCCACAC	GGCAACAGACATATCCTCCA
<i>MyoD</i>	myogenic differentiation 1	TCCCTAAGCGACACAGAACA	CGAAAGGACAGTTGGGAAGA
<i>Ucp2</i>	uncoupling protein 2	GGTCGGAGATACCAGAGCAC	TGAGGTTGGCTTTCAGGAGA
<i>Pax7</i>	paired box 7	AAAGCCAAACACAGCATCG	GTCGGGTTCTGATTCCACAT
<i>Igfl</i>	insulin like growth factor 1	GCTCTTCAGTTCGTGTGTGG	CACAATGCCTGTCTGAGGTG
<i>Ppargc1a</i>	PPARG coactivator 1 alpha	AGCCGTGACCACTGACAACGAG	GCTGCATGGTCTGAGTGCTAAG